Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release Tolterodine

被引:0
作者
Birgitta Olsson
Johan Szamosi
机构
[1] Experimental Medicine,Division of Pharmacia
[2] Biovitrum,Department of Biostatistics
[3] Quintiles Services,undefined
来源
Clinical Pharmacokinetics | 2001年 / 40卷
关键词
Overactive Bladder; Extended Release; Tolterodine; Poor Metabolisers; Extensive Metabolisers;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:227 / 235
页数:8
相关论文
共 62 条
[11]  
Nilvebrant L.(1999)Serum protein binding of tolterodine and its major metabolites in humans and several animal species Biopharm Drug Dispos 20 91-9
[12]  
Postlind H.(1999)Tolterodine is effective and well tolerated during long-term use in patients with overactive bladder [abstract] J Urol 161 35-43
[13]  
Danielson A.(2001)Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder Clin Pharmacokinet 40 135-7
[14]  
Lindgren A.(1992)Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population Clin Pharmacol Ther 51 12-65
[15]  
Mahgoub J.R.(1997)Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry J Pharm Biomed Analysis 16 155-61
[16]  
Idle L.G.(1993)Differences of chronopharmacokinetic profiles between Propranolol and atenolol in hypertensive subjects J Clin Pharmacol 33 756-5
[17]  
Dring G.(1995)Diurnal variation in the pharmacokinetics of nizatidine in healthy volunteers and in patients with peptic ulcer disease J Clin Pharmacol 35 1071-905
[18]  
Alván P.(1997)Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects Antimicrob Agents Chemother 41 898-63
[19]  
Bechtel L.(1997)Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients Pharmacotherapy 17 457-96
[20]  
Iselius N.(1999)Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin J Clin Pharmacol 39 289-18